Creative Medical (NASDAQ: CELZ) targets H1 2026 data from ADAPT; secures 2 U.S. patents
- Posted on October 27, 2025
- By Google News
- 3 Views
Creative Medical (NASDAQ: CELZ) targets H1 2026 data from ADAPT; secures 2 U.S. patents
Letter details FDA-cleared ADAPT (Fast Track) and CREATE-1 trials; H1 2026 topline and early 2026 data. Two U.S. patents in Q3 2025, terms to 2043/2042.
